ILX-002
Small molecule therapeutic
An oral small molecule that binds hemoglobin S and directly inhibits its polymerization in sickle cell disease. It is in preclinical development.
- Direct hemoglobin S polymerization inhibitor
- Oral, once-daily dosing goal
- Preclinical stage, clinical trials planned
Built for
Sickle cell disease patients and the hematology clinicians who treat them